Abstract: We aimed to provide detailed utilization data on the total use of non-vitamin K antagonist oral anticoagulants (NOACs) since their introduction in 2008. Using the nationwide Danish National Prescription Registry, we identified all individuals filling prescriptions for NOACs 2008-2016. We reported the development in incident and prevalent users and explored baseline characteristics and treatment persistence according to treatment indication. A total of 126,691 NOAC users were identified within the Danish population of 5.7 million inhabitants. The annual incidence and prevalence increased rapidly reaching 10 and 17 per 1000 individuals in 2016. Patients received NOACs due to atrial fibrillation (AF) (43%), venous thromboembolism (VTE) prophylaxis after arthroplastic surgery (17%), VTE (12%) and no registered indication (28%). The most frequently used NOAC was rivaroxaban (n = 52,431), followed by dabigatran (n = 47,067), apixaban (n = 27,116) and edoxaban (n = 77). The proportion of AF and VTE patients initiating low-dose NOACs were between 23% and 50%. Patients treated with NOAC for VTE primarily received rivaroxaban. We observed a trend towards increased use of apixaban and rivaroxaban at the expense of dabigatran. Treatment persistence was highly dependent on treatment indication. Persistence to NOAC after 3 years was only 62% in AF compared to 28% for VTE. We documented an accelerating increase in the use of all four NOACs in the first 8 years after introduction. We have identified areas requiring further attention, including reasons for missing indications, potential inappropriate dosing and low long-term persistence with NOACs in patients with AF.
Introduction
Non-vitamin K antagonist oral anticoagulants (NOACs) directly target specific coagulation factors and include the factor IIa (thrombin) inhibitor dabigatran and the factor Xa inhibitors apixaban, rivaroxaban and edoxaban. The first NOAC was introduced in Europe in 2008 as prophylaxis against venous thromboembolism after arthroplastic surgery. Since then, all NOACs have been approved for stroke prophylaxis in atrial fibrillation (AF) and for treatment of deep venous thromboembolism and pulmonary embolism (collectively 'venous thromboembolism', VTE).
Despite the rapid and extensive uptake of NOACs in Denmark [1, 2] , the actual clinical use of these drugs remains to be described in full. Description and evaluation of the utilization of NOACs in daily practice are important to, for example, (i) evaluate whether NOACs are used as recommended in clinical guidelines, (ii) describe selective prescribing of NOACs of potential impact to future comparative safety and effectiveness studies and (iii) identify areas of NOAC use requiring further attention.
Previous studies reporting on the utilization patterns of NOACs have mainly focused on the use of NOACs for specific indications, most often AF [3] [4] [5] , defined by the presence of specific registered diagnoses in healthcare registries serving as proxies for the treatment indication. This method leads to a large number of NOAC users without a registered treatment indication proxy being excluded from these studies [1, 3, 6] , thus, potentially missing important information on a substantial proportion of the population of NOAC users.
The Danish registries provide some of the best sources for observational research in the world due to complete nationwide coverage and the unique civil registration number assigned to all Danish citizens allowing linkage between all registries. Using these nationwide Danish health registries, we aimed to provide detailed utilization data on the total use of NOACs since their introduction to the market without restricting to a specific patient group. The objectives of the study were to describe the utilization of NOACs over time as well as potential differences in characteristics of NOAC users according to treatment indication and NOAC type and also to investigate the persistence to NOAC therapy in the context of different indications.
Methods
Design and setting. This was a population-based study describing the complete cohort of Danish NOAC users during the period of March 2008 to the end of 2016, that is, the entire period, NOACs have been available in Denmark. The total Danish population increased from 5.48 million to 5.75 million during the study period [7] .
Data sources. Denmark provides tax-supported health care to all citizens, securing free and equal access to general practitioners and hospitals as well as partial reimbursement for most prescribed medications [8] . To maintain and administer this healthcare system, numerous registries have been established. The civil registration number, a unique 10-digit personal identifier, enables linkage between all registries and thereby allows the conduction of true populationbased studies covering all residents in Denmark [9] .
Data regarding use of NOACs and other drugs were obtained from the Danish National Prescription Registry, which contains complete information on all prescription drugs dispensed to Danish citizens since 1995; including information on the Anatomical Therapeutic Chemical (ATC) classification code of the dispensed drug, date of purchase, package size in defined daily doses, tablet/capsule strength and civil registration number [10] . Information on duration and indication for treatment is not available in the Prescription Registry. Data used to describe the study population with regard to diagnoses (including proxies for anticoagulant treatment indication) and surgical procedures were obtained from the Danish National Patient Registry, which includes information from Danish hospitals on in-and outpatient diagnoses and surgical procedures with complete nationwide coverage since 1978. Overall, positive predictive values of diagnoses registered in the Patient Register are high. For some conditions, the completeness of the register may, however, be limited by the lack of primary care data [11] . Definitions of drugs, diagnoses, operations and procedures used in this study are detailed in Appendix 1.
Study cohort. The study cohort comprised all patients with a firsttime treatment episode of NOAC use. Patients entered the cohort when filling their first (incident) NOAC prescription at a Danish community pharmacy during the study period as registered in the Prescription Registry. The date of the first prescription fill was set as the index date. Patients left the cohort upon discontinuation of NOAC treatment (defined below), death or migration. Thus, only the first treatment episode of NOAC use for each patient was considered.
Study drugs. All four NOACs with market authorization in Denmark, that is dabigatran (Pradaxa â ), rivaroxaban (Xarelto â ), apixaban (Eliquis â ) and edoxaban (Lixiana â ), were included in the study. Indications, dosing regimens and availability of NOACs including marketing dates for the various indications are provided in tables 1 and 2. Low-dose NOAC treatment was defined as treatment with dabigatran 75 mg or 110 mg, rivaroxaban 2.5 mg, 10 mg or 15 mg and apixaban 2.5 mg. All NOACs are reimbursed by the Danish National Health Service.
Indication for NOAC use. The study cohort of NOAC users was described according to assumed treatment indication. Accordingly, all NOAC initiators were labelled with one of the following major indications: AF, VTE, thromboprophylaxis after knee and hip replacement or no registered indication. Some patients with an indication for anticoagulant treatment, such as patients with valvular heart disease or valvular atrial fibrillation, are not eligible for treatment with NOAC. Rivaroxaban is also registered for use in acute coronary syndromes (ACS), but use for this indication has been very limited in Denmark and thus was not considered in this study.
AF and VTE were defined by relevant diagnoses (see Appendix 1) registered at any time-point before NOAC initiation in the Patient Registry, while also including AF diagnoses registered up to 90 days after NOAC initiation to allow for diagnostic lag [4] . If patients were registered with both a diagnosis of AF and VTE, they were classified as AF, unless the diagnosis of VTE was given within 1 year before NOAC initiation. Patients registered for a hip or knee replacement 2 weeks before or 5 weeks after NOAC initiation were classified as such.
Baseline characteristics of NOAC initiators. Baseline characteristics were assessed at the index date. The following characteristics were included: (i) age and sex; (ii) chronic diseases associated with an increased risk of bleeding and/or thromboembolism (including registration of the following diagnosis within 5 years before index date: alcohol abuse, cancer, chronic renal failure, dialysis, diabetes, hypertension, ischaemic heart disease, liver failure, peripheral arterial disease, any previous bleeding, ischaemic stroke/transient ischaemic attack and chronic heart failure); (iii) prescriptions for platelet inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) or selective serotonin reuptake inhibitors (SSRIs) filled within 180 days before index date; (iv) previous VKA use defined by having filled one or more prescriptions for VKA within 5 years before index date; (v) type and start dose of NOAC.
Analyses. Firstly, we estimated the annual incidence rate and prevalence proportion of use for all NOACs combined as well as separately for each NOAC. These were calculated as the number of first-ever and current users per 1000 individuals in the Danish population. Calculations were performed with the total Danish population on 1 January in the relevant year as the denominator, as the number of prevalent users is negligible. Patients were considered 'on treatment' for the subsequent number of days corresponding to the number of tablets in a package for rivaroxaban and edoxaban (used once daily) or half the number of tablets for dabigatran and apixaban (used twice daily). Finally, a 60-day grace period was added to account for minor non-compliance and irregular prescription refills. A patient was considered as having discontinued treatment if not filling a new prescription for the same or another NOAC after the estimated prescription duration plus the grace period or upon switching to VKA, defined as filling a prescription for VKA during NOAC therapy.
Secondly, we calculated the sex-and age-specific annual prevalence proportion for the last year of the study period (2016) using the Danish population in relevant age and sex strata as the denominator.
Thirdly, we stratified baseline characteristics of NOAC users on the assumed indication for treatment and according to type of NOAC initially prescribed. Stratified on indication, we also calculated the proportion of patients receiving various NOAC doses.
Fourthly, we calculated the relative distribution between the four included indications for NOAC use for each year throughout the study period. Further, in a post hoc analysis, we calculated the proportion of patients receiving NOAC for one of the four indications and explored the development in this distribution each year throughout the study period.
Fifthly, we calculated the persistence to NOAC use according to indication. For each NOAC user, treatment persistence was assessed from the day of the first prescription fill. NOAC treatment was considered as discontinued according to the definition above. Switching between NOACs was allowed. A drug survival curve (Kaplan-Meier plot) showing treatment persistence stratified on the three major indications, and no registered indication was produced. Further, a sensitivity analysis was performed with a grace period of 90 days.
Ethics
According to Danish law, ethical approval is not required for register-based studies [8] .
Results
Incidence and prevalence of NOAC use. We identified a total of 126,691 individuals initiating NOAC therapy from 2008 to the end of 2016. The most frequently used NOAC over the entire period was rivaroxaban (n = 52,431), followed by dabigatran (n = 47,067), apixaban (n = 27,116) and, finally, edoxaban (n = 77). The number of incident users per 1000 individuals increased from 0.06 to 10 during the study period ( fig. 1A ). This was accompanied by a close to 300-fold increase in the prevalence proportion from 0.06 to 17 per 1000 individuals ( fig. 1B) . The annual number of dabigatran users increased until 2014 (n = 21,907; 48% of all NOAC users in 2014) followed by a decline in the subsequent years (n = 18,838; 24% of all NOAC users in 2016). Until 2012, the use of rivaroxaban was limited. However, after 2012, use of rivaroxaban increased steadily each year reaching a total of 30,966 users in 2016, hereby accounting for 40% of all NOAC use. Similarly, we observed an increase in apixaban use from 17,931 users in 2015 to 27,312 users in 2016 accounting for 35% of incident NOAC users in 2016 1A ). The use of edoxaban (n = 77) was too limited to be distinguishable in fig. 1A ,B.
Baseline characteristics. Tables 3 and 4 present baseline characteristics of the study cohort stratified by assumed treatment indication and type of NOAC. A greater proportion of patients using NOAC for VTE prophylaxis related to arthroplastic surgery had recently filled a prescription for NSAID (65%) and PPIs (45%) when compared to other indications. The prevalence of previous VKA use was highest among patients using NOACs for AF and VTE (34% and 31%, respectively, versus 3-15% for other indications) and likewise for edoxaban users. Baseline characteristics for patients with no registered indication were similar to those of the patients receiving NOAC due to AF, except that substantially more patients with AF had previously received VKA and that more patients with AF were treated with dabigatran (43% versus 30%).
Overall, 55.116 individuals (44% of all NOAC users) received NOAC due to AF. Of these, most individuals received dabigatran (43%), followed by apixaban (29%) and rivaroxaban (28%). Nearly, all individuals initiating NOACs as VTE prophylaxis related to arthroplastic surgery (21,531, 17% of all NOAC users) received either dabigatran or rivaroxaban (55% and 45%), whereas individuals with VTE (14,828; 12% of all NOAC users) primarily received rivaroxaban (77%). Approximately half of the individuals filling a prescription for dabigatran, apixaban or edoxaban could be classified as having AF compared to one-third of rivaroxaban users (table 4) . In general, there were minor differences in the prevalence of comorbidities and concomitant medication between users of the various NOACs, although apixaban users had a higher prevalence of previous bleeding, stroke and chronic heart failure (13%, 17% and 17%, respectively) than users of the other NOACs. For all four NOACS, more male than female users were observed. Age and sex distribution. The full age spectrum for prevalence in 2016 stratified by gender is provided in fig. 2 , showing a more frequent use with increasing age and for all ages a greater proportion of male users, for example, 3% of men aged 65 years compared to 11% of men aged 85 years. Figure 3 shows that, the first 3 years after NOAC was introduced, they were mainly used for the only registered indication: VTE prophylaxis after hip or knee surgery (86-90%).
Distribution among indications.
From 2010 to 2015, this proportion dropped from 89% to 2%. Figure 3 also shows a shift in the distribution from 2011 to the end of the study period towards an increased proportion of AF patients. Further, the proportion of patients receiving NOACs for no registered indication increased each year from 9% in 2009 to 35% in 2016.
Treatment persistence. Figure 4 shows that persistence with NOAC use was largely dependent on indication. After 1.5 years, 72% of individuals with AF were still on continuous treatment with a NOAC compared to 55% for no registered indication and 36% for VTE. Treatment persistence for VTE prophylaxis after hip and knee replacement dropped to 5% after 120 days.
Treatment persistence among patients with AF continued to drop, and after 3 years, 38% of AF patients had discontinued NOAC therapy. When changing the grace period to either 30 or 90 days, the treatment persistence for AF patients changed to 47% and 69% after 3 years (see Appendix 2) .
Discussion
This study showed a rapid increase in the use of NOAC since their introduction in 2008 reaching a prevalence of 17 per 1000 individuals (2%) in Denmark by the end of 2016. We documented an increase in both incident and prevalent users of all four NOACs, although use of edoxaban was limited. The prevalence of NOAC use increased with higher age, with a prevalence >10% among men aged 85 years or older. The main indication for NOAC treatment was AF. Patients with AF presented with higher age and more comorbidity, such as stroke and chronic heart failure comprising a patient group at higher risk compared to patients with VTE. Lastly, this study found that continuous long-term treatment with NOACs in AF patients was limited. Patients with VTE were primarily treated with rivaroxaban. Contrary to AF, treatment persistence for VTE was more in alignment with treatment recommendations. A total of 11,767 individuals (accounting for 25% of all dabigatran users) initiated dabigatran for VTE prophylaxis in relation to knee and hip replacement. Dabigatran was approved for treatment of AF in Denmark in 2011 followed by a rapid increase in its use ( fig. 1A) [4] . This increase most likely reflects that the total number and fraction of AF patients initiating OAC treatment have increased in Denmark during the last years [16] . Later, a drop in the use of dabigatran was observed, which could be explained by the change in regional guideline recommendations during the study period favouring mainly rivaroxaban and apixaban.
Venous thromboembolism prophylaxis in relation to arthroplastic surgery was the first approved indication for NOAC use. In the wake of studies comparing dabigatran and rivaroxaban to enoxaparin (Dabigatran Etexilate in Extended Venous Thromboembolism Prevention After Hip Replacement Surgery NOAC, non-vitamin K antagonist oral anticoagulants; VTE, venous thromboembolism; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; SSRIs, selective serotonin reuptake inhibitors; VKA, vitamin K antagonist.
(RE-NOVATE) [12] and Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism (RECORD) [13] ), a change in treatment regimens and clinical guidelines for VTE prophylaxis in relation to arthroplastic surgery followed, as both NOACs were non-inferior in terms of efficacy and with no need for monitoring [14] . Accordingly, our study showed that 21,531 individuals (accounting for 17% of total NOAC users) filled a NOAC prescription for this indication. Most of these patients were treated with either dabigatran or rivaroxaban. Apixaban is also approved for this indication (May 2011). However, a very limited use was observed in our study (1%), although studies show a favourable safety profile [15, 16] . Rivaroxaban and apixaban were approved for stroke prophylaxis in patients with AF in February and December 2012. We observed a large increase in the total use of these NOACs from 2014 to 2016. Several factors may have contributed to the difference in initial uptake among NOACs, such as different branding strategies from the pharmaceutical companies upon introduction and changes in guidelines for anticoagulant treatment in AF patients recommending NOAC rather than VKA [17] . Individuals receiving apixaban for AF had a higher percentage of previous bleeding, stroke and chronic heart failure. This might be explained by selective prescribing due to the low risk of bleeding with apixaban [18] [19] [20] , especially in the elderly [21] .
Rivaroxaban was the first NOAC to be approved for treatment of VTE, and throughout our study period, it has been the preferred NOAC for this indication, accounting for 77% of The sex and age distribution of all NOAC users in 2016 displayed as annual prevalence proportion, showing an increasing prevalence with increasing age and for all ages a higher prevalence for males.
all users for this indication. This is likely explained by the recommendations in Danish guidelines [22] along with the regional pricing of NOAC favouring rivaroxaban. Apart from the once-daily dosing, rivaroxaban (and apixaban) are the only NOACs providing a single oral drug strategy with no need for heparin lead-in. Similar to our findings, Urbaniak et al. [23] also found rivaroxaban to be the preferred NOAC for VTE patients in Norway. The development in edoxaban use is difficult to investigate in this study due to the low number of users, but the use of edoxaban has recently been explored in more detail [6] documenting a slow but increasing use of edoxaban.
The study also showed that edoxaban is primarily used in patients with AF. The baseline characteristics for edoxaban users are generally similar to users of other NOACs, except that the vast majority have switched from other previous OAC treatment.
In the present study, we found 36,347 individuals (28%) receiving NOACs with no identifiable indication according to available ICD codes. In 2009, the share of NOAC initiators where no apparent indication could be identified was 9%. This share increased to 38% in 2016. Drug users without a registered indication may reflect additional time lag between diagnosis and registration of the indication than accounted for in Treatment persistence 3 years forward from treatment initiation for each indication to NOAC, defined as number of days corresponding to the number of tablets in a package for rivaroxaban and edoxaban (used once daily) or half the number of tablets for dabigatran and apixaban (used twice daily) plus a 60-day grace period. our study [4] , under-reporting (i.e. suboptimal specificity) in healthcare registries, off-label use (e.g. use for cerebral venous thrombosis [24] and heparin-induced thrombocytopenia [25] ) or that some patients with indications for NOACs are for some reason not 'selected' for hospital management of their condition, hence never receiving a hospital diagnosis, for example AF. Patients solely treated in primary care may contribute to this, but as we did not have access to information regarding prescriber type, we could not explore this in the present study. As individuals with no registered indication are most often excluded in studies on NOACs [1, 4] , this patient group should be further explored. In our study, baseline characteristics of these patients were similar to patients with AF (table 3) .
The proportion of AF and VTE patients initiating the lower dose of dabigatran (110 mg) was 38% and 50% of all dabigatran initiators, respectively. This dose is recommended for individuals aged ≥80 years, patients with concomitant treatment with verapamil, high risk of bleeding and low risk of thromboembolism or GFR 30-50 ml/min. [26] . A Danish study by Nielsen et al. [27] on reduced NOAC doses in AF explored patients initiating a reduced dose with regard to age and chronic kidney disease. Based on their results, it is suspected that a considerable number of patients are inappropriately underdosed, that is, receiving the lower dose without fulfilling the criteria for this (table 1). The same concern applies for rivaroxaban and apixaban. In this study, we documented that 23% and 35% of AF patients receiving rivaroxaban or apixaban received the low dose (15 and 2.5 mg). Previous studies have reported underdosing of NOACs among physicians due to fear of bleeding risk [28] . As most studies supporting the use of NOACs over warfarin were conducted with the standard NOAC dose, patients not treated according to current guidelines may not benefit as well as expected.
During our study, rivaroxaban 2.5 mg bid was only approved for ACS. One hundred patients were treated with this dose (table 5) . However, half of these were classified as patients with either AF or VTE. This may reflect physicians not registering an ACS diagnosis for patients hospitalized for AF or VTE. Presuming that rivaroxaban 2.5 mg is dispensed correctly in daily clinical practice, our study finds that rivaroxaban is only rarely used in patients with ACS.
Treatment persistence with NOACs was highly dependent on indication. Guideline recommendations for the duration of anticoagulant treatment in patients with VTE vary between 3 and 12 months depending on patient characteristics and the presumed balance between the risk of recurrence and bleeding [29] . Our results likely reflect this variation, as treatment persistence for VTE steadily dropped within a year of treatment. As anticoagulant treatment for AF is considered to be lifelong, it is remarkable that our results suggest that only 63% are still on continuous NOAC treatment after 3 years, that is, have had no break between periods covered by a prescription exceeding 60 days. An Australian study conducted by Simons et al. [30] found treatment persistence for any NOAC to be 48% after 2.5 years. Importantly, we employed a definition of persistence requiring uninterrupted use of NOACs with a grace period of no more than 60 days. This was chosen due to very short half-lives of all NOACS and the consequences of breaks and discontinuation of OAC treatment with even short treatment breaks potentially leading to increased stroke risk [31, 32] . Our findings suggest that more research on both persistence and adherence to NOAC treatment among AF patients is needed in order to explore the prognosis in patients with AF stopping anticoagulant treatment and to identify predictors of low adherence.
A major strength of our study is the inclusion of all NOAC users in the study period from Danish national registries covering the entire Danish population including high-quality data on prescription records [11] . A limitation is the lack of information on clinical data such as body-weight and creatinine clearance, which influence the choice and dosing of NOACs [33] . Further, indications for NOACs were defined according to hospital diagnoses. As discussed previously, these definitions may be subject to limitations such as greater diagnostic lag [4] or patients treated outside hospital care, for example patients treated in primary care.
Conclusion
This study documents a rapid increase in the use of all four NOACs in the first 8 years after NOACs were introduced in Denmark. Importantly, we have identified areas requiring further attention, such as the reasons for missing indications in a large proportion of patients, low long-term persistence with NOACs in AF patients and potential inappropriate dosing. Exploring these areas in more detail may guide clinicians to safer and more rational use of NOACs.
